Literature DB >> 8729060

Early action potential shortening in hypoxic hearts: role of chloride current(s) mediated by catecholamine release.

E Ruiz Petrich1, A Ponce Zumino, O F Schanne.   

Abstract

We tested the hypothesis that the early action potential shortening induced by hypoxia in perfused hearts is attributable to chloride currents activated or modulated by endogenous catecholamine release. Rabbit hearts perfused at 33 degrees C and paced at 2.5-2.8 Hz were used for membrane potential recordings with microelectrodes. Catecholamine depletion was induced with reserpine treatment. The effects of nadolol (10 microM), the stilbenedisulfonic acid derivatives DIDS (10 microM) and SITS (1 mM), and diphenylamine-2 carboxylate (DPC, 100 microM) on action potential characteristics were determined at different times during hypoxia. The effect of chloride transport blockers on the outward currents induced by 200 nM carbonyl cyanide (CCCP) or by 1 microM isoproterenol in isolated cells was also tested. In control hearts, action potential duration (APD) at 25 and 95% repolarization decreased by 50 +/- 9% and 32 +/- 7% respectively after 5 min of hypoxia. This effect was fully antagonized by reserpine pretreatment, by respiratory acidosis, and by nadolol when present from the beginning of hypoxia. None of these agents affected action potential characteristics in normoxia and nadolol had no effect when added after 15 min of hypoxia. Lowering the chloride concentration to 17.5 mM reproduced the effects of nadolol and reserpine. DIDS and SITS lengthened APD in normoxia and attenuated the early APD shortening in hypoxia. DPC had no effect in normoxia but fully counteracted APD shortening produced by isoproterenol or early hypoxia. In isolated cells, DIDS did not affect the glibenclamide sensitive outward current induced by CCCP and DPC blocked the isoproterenol induced current. The data suggest that in whole hearts, chloride currents mediated by endogenous catecholamine release are involved in the early action potential shortening induced by hypoxia with preservation of glycolysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8729060     DOI: 10.1006/jmcc.1996.0026

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  IK1 and cardiac hypoxia: after the long and short QT syndromes, what else can go wrong with the inward rectifier K+ currents?

Authors:  Yanfang Xu; Qian Zhang; Nipavan Chiamvimonvat
Journal:  J Mol Cell Cardiol       Date:  2007-04-29       Impact factor: 5.000

Review 2.  Phenomics of cardiac chloride channels: the systematic study of chloride channel function in the heart.

Authors:  Dayue Duan
Journal:  J Physiol       Date:  2009-01-26       Impact factor: 5.182

3.  Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury.

Authors:  Sunny Yang Xiang; Linda L Ye; Li-lu Marie Duan; Li-hui Liu; Zhi-dong Ge; John A Auchampach; Garrett J Gross; Dayue Darrel Duan
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

4.  RSD1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits.

Authors:  T D Barrett; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  Cardiac IK1 underlies early action potential shortening during hypoxia in the mouse heart.

Authors:  Lin Piao; Jingdong Li; Meredith McLerie; Anatoli N Lopatin
Journal:  J Mol Cell Cardiol       Date:  2007-04-10       Impact factor: 5.000

Review 6.  Phenomics of cardiac chloride channels.

Authors:  Dayue Darrel Duan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

7.  Role of action potential configuration and the contribution of C²⁺a and K⁺ currents to isoprenaline-induced changes in canine ventricular cells.

Authors:  N Szentandrássy; V Farkas; L Bárándi; B Hegyi; F Ruzsnavszky; B Horváth; T Bányász; J Magyar; I Márton; P P Nánási
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.